<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ANISINDIONE</span><br/>(an-i-sin-dye'one)<br/><span class="topboxtradename">Miradon<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators &amp; anticoagulants</span>; <span class="classification">anticoagulant</span><br/><b>Prototype: </b>Warfarin Sodium<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Anisindione inhibits precursor proteins of clotting factors II, VII, IX, and X. Anisindione inhibits formation of the active
         form of vitamin K. Therefore, levels of the active form of vitamin K are depleted.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduction of active levels of vitamin K reduces levels of active clotting factors, and thus produces an anticoagulation effect.
         The anticoagulant effect inhibits further formation of thrombi. Anisindione does not have a direct thrombolytic effect.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis and treatment of venous thrombosis (including in atrial fibrillation) and pulmonary embolism; adjunct in treatment
         of coronary occlusion.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category X); labor and delivery; lactation. Hemorrhagic tendencies or blood dyscrasias; recent cerebral hemorrhage;
         GI ulcer or ulcerative colitis; open wounds.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Recent surgery of brain, eye, spinal cord, prostate; renal or hepatic disease; severe diabetes; bacterial endocarditis, pericarditis
         or polyarthritis; diverticulitis or visceral carcinoma; aneurysm, severe or malignant hypertension, eclampsia, or preeclampsia;
         possible abortion; malnutrition, emaciation, deficiencies of vitamin C or K; patient noncompliance; elderly females; patients
         deficient in protein C; congestive heart failure.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Anticoagulation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg day 1, 200 mg day 2, then 100 mg q.d. Adjust dose to maintain desired PT level (dose range 25250 mg)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Take at the same time each day.</li>
<li>Store in a tightly closed container between 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Pyrexia. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea. <span class="typehead">Hematologic:</span>
<span class="speceff-both">Hemorrhage</span>. <span class="typehead">Skin:</span> Dermatitis, urticaria, alopecia. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Anisindione may cause alkaline urine to be red-orange; may enhance <span class="alt">uric acid</span> excretion, cause elevation of <span class="alt">serum transaminases,</span> and may increase <span class="alt">lactic dehydrogenase</span> activity.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> In addition to the drugs listed below, many other drugs have been reported to alter the expected response to anisindione;
      however, clinical importance of these reports has not been substantiated. The addition or withdrawal of any drug to an established
      drug regimen should be made cautiously, with more frequent <b>INR</b> determinations than usual and with careful observation of the patient and dose adjustment as indicated. The following may
      enhance the anticoagulant effects of anisindione: <b>Acetohexamide,</b>
<b>acetaminophen,</b>
<span class="classification">alkylating agents</span>, <b>allopurinol,</b>
<span class="classification">aminoglycosides</span>, <b>aminosalicylic acid,</b>
<b>amiodarone,</b>
<span class="classification">anabolic steroids</span>, <span class="classification">antibiotics (oral)</span>, <span class="classification">antimetabolites</span>, <span class="classification">antiplatelet drugs</span>, <b>aspirin,</b>
<b>asparaginase,</b>
<b>capecitabine,</b>
<b>celecoxib,</b>
<b>chloramphenicol,</b>
<b>chlorpropamide,</b>
<b>chymotrypsin,</b>
<b>cimetidine,</b>
<b>clofibrate,</b>
<b>co-trimoxazole,</b>
<b>danazol,</b>
<b>dextran,</b>
<b>dextrothyroxine,</b>
<b>diazoxide,</b>
<b>disulfiram,</b>
<b>erythromycin,</b>
<b>ethacrynic acid,</b>
<b>fluconazole,</b>
<b>glucagons,</b>
<b>guanethidine,</b> hepatotoxic drugs, <b>influenza vaccine,</b>
<b>isoniazid,</b>
<b>itraconazole,</b>
<b>ketoconazole,</b>
<span class="classification">mao inhibitors</span>, <b>meclofenamate,</b>
<b>mefenamic acid,</b>
<b>methyldopa,</b>
<b>methylphenidate,</b>
<b>metronidazole,</b>
<b>miconazole,</b>
<b>mineral oil,</b>
<b>nalidixic acid,</b>
<b>neomycin (oral),</b>
<span class="classification">nonsteroidal anti-inflammatory drugs</span>, <b>plicamycin,</b>
<span class="classification">potassium products</span>, <b>propoxyphene,</b>
<b>propylthiouracil,</b>
<b>quinidine,</b>
<b>quinine,</b>
<b>rofecoxib,</b>
<b>salicylates,</b>
<b>streptokinase,</b>
<b>sulindac,</b>
<span class="classification">sulfonamides</span>, <span class="classification">sulfonylureas</span>, <span class="classification">tetracyclines</span>, <span class="classification">thiazides</span>, <span class="classification">thyroid drugs</span>, <b>tolbutamide,</b>
<span class="classification">tricyclic antidepressants</span>, <b>urokinase,</b>
<b>vitamin E,</b>
<b>zileuton.</b> The following may increase or decrease the anticoagulant effects of anisindione: <b>Alcohol</b> (acute intoxication may increase, chronic alcoholism may decrease effects), <b>chloral hydrate,</b>
<span class="classification">diuretic</span>. The following may decrease the anticoagulant effects of anisindione: <b>barbiturates,</b>
<b>carbamazepine,</b>
<b>cholestyramine,</b>
<span class="classification">corticosteroids</span>, <b>corticotropin,</b>
<b>ethchlorvynol,</b>
<b>glutethimide,</b>
<b>griseofulvin,</b>
<span class="classification">laxatives</span>, <b>mercaptopurine,</b>
<span class="classification">oral contraceptives</span>, <b>rifampin,</b>
<b>spironolactone,</b>
<b>vitamin C,</b>
<b>vitamin K.</b>
<span class="typehead">Herbal:</span>
<b> Capsicum,</b>
<b>celery,</b>
<b>chamomile,</b>
<b>clove,</b>
<b>Devil's claw,</b>
<b>Dong quai,</b>
<b>Echinacea,</b>
<b>fenugreek,</b>
<b>feverfew,</b>
<b>garlic,</b>
<b>ginger,</b>
<b>ginkgo,</b>
<b>horse chestnut,</b>
<b>licorice root,</b>
<b>passionflower herb,</b>
<b>tumeric,</b>
<b>willow bark</b> may increase risk of bleeding; <b>ginseng,</b>
<b>green tea,</b>
<b>St. John's wort</b> may decrease effectiveness of anisindione. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Well absorbed. <span class="typehead">Peak:</span> 23 d. <span class="typehead">Duration:</span> 13 d. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 35 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine PT/INP prior to initiation of therapy and then daily until maintenance dosage is established.</li>
<li>Obtain a <small>CAREFUL</small> medication history prior to start of therapy and whenever altered responses to therapy require interpretation; extremely
            <small>IMPORTANT</small> since many drugs interfere with the activity of anticoagulant drugs (see <small>INTERACTIONS</small>).
         </li>
<li>Adjust dose to maintain PT at 1.21.5 times the control or another parameter set by physician.</li>
<li>Lab tests: For maintenance dosage, PT/INR determinations at 14-wk intervals, or more often, depending on patient's response;
            periodic Hct, Hgb, platelet count, WBC with differential, urinalyses, stool guaiac, and liver and kidney function tests.
         </li>
<li>Monitor closely whenever a new drug is added or removed from the regimen.</li>
<li>Assess all systems carefully for S&amp;S of hemorrhage.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician immediately if you experience any of the following: unusual bleeding or bruising, black or bloody stools,
            blood in urine, unexplained tiredness or fever, chills or sore throat, or stomach pain.
         </li>
<li>Avoid aspirin or other anti-inflammatory pain relievers while taking this drug.</li>
<li>Do not increase your consumption of foods containing vitamin K, such as liver, green leafy vegetables, broccoli, or cauliflower,
            without discussing your diet with your doctor.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>